HAFG
VRTX icon

Hansen & Associates Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Hansen & Associates Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-441
Closed -$204K – 48
2025
Q4 		$204K Buy
+441
New +$190K 0.11% 46

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hansen & Associates Financial Group's VRTX Position: Q1 2026 in Review

Hansen & Associates Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 441 shares — an estimated $204K sold.

Hansen & Associates Financial Group first reported a position in VRTX in Q4 2025 and held it in 1 quarter. The position peaked at $204K in Q4 2025. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Hansen & Associates Financial Group reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hansen & Associates Financial Group sold 441 Vertex Pharmaceuticals shares in Q1 2026, an estimated $204K.
  • Hansen & Associates Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Hansen & Associates Financial Group's Vertex Pharmaceuticals position peaked at $204K in Q4 2025.
  • 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Hansen & Associates Financial Group's 13F filing for Q1 2026, filed 11 May 2026.